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TB does not respect artifi cial barriers, whether they are prisons, 
walls, or international frontiers
Navigator – Stephen Williams
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(Variable dimensions) ‘I don’t want anything for me.
I only wish for the possible impossible:
A world without victims.’
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CHAPTER 5
Hazel M Dockrell   
T Cell Protective Immune 
Responses against Tuberculosis
Introduction 
T cell immunity to MTB is both straightforward and incredibly complex. 
Th is chapter will focus on results obtained from studies of human T cells, but 
draw on studies in murine models where appropriate. It will provide a brief 
overview of the main roles played by T cells in immunity to MTB, highlight 
some areas of recent research, discuss some of the ways in which T cell immune 
responses can be measured in vaccine trials, and identify areas where further 
research is needed. 
T Cell Immunity to MTB
Th ere is no question that T cells play a central and essential role in protection 
against progressive infection with MTB. On a simplistic level, activation of 
CD4+ T cells leads to secretion of cytokines such as IFN-γ and TNF-α that 
induce macrophage activation, with induction of bactericidal products such 
as nitric oxide and reactive oxygen intermediates (1, 2). Th e central role of 
CD4+ T cells in protection against MTB infection is also illustrated by the 
marked susceptibility to TB in individuals whose CD4+ T cell function and 
CD4+ T cell numbers are reduced due to HIV infection (3), and depletion of 
mycobacteria-specifi c CD4+ T cells is detectable shortly aft er HIV infection 
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(4). However, CD4+ T cells may also orchestrate responses within other T cell 
subsets, as discussed below.
Secretion of chemokines such as CCL2, CCL3, CCL5, and TNF-α by infected 
macrophages attracts T cells to the site of infection (5). Perturbations of the 
balance between cytokine and chemokine production may occur in diff erent 
forms of TB (6). In murine models, both CD4+ and CD8+ T cells are present 
within the granulomas that result, together with the classic hallmark cells 
of such granulomas, macrophages, and giant cells (7, 8). New technologies 
allow the imaging of granulomas within both animal and human lungs and 
in zebrafi sh (9, 10), and this is an active area of research. 
The Tuberculin Skin Test
Th e most widely used test of T cell immunity to MTB is the Tuberculin Skin 
Test (TST), which measures induration two to three days aft er intradermal 
injection of purifi ed protein derivative (PPD). Th is response involves monocytes 
and previously primed memory T cells, which are attracted to the skin where 
they proliferate and secrete cytokines (11). Th e resulting induration provides 
a read-out of immunity that is, however, not MTB specifi c, as indurations of 
<10mm may be caused by prior BCG vaccination. Although large indurations 
of >15mm are associated with a greater risk of developing clinical TB, smaller 
indurations may be associated with protection from the disease (12)—one 
example of how T cell activation in the ‘right’ amounts can be protective 
but excessive responses may be associated with pathology. A lower cut-off  
to identify ‘positive’ responses, of >5mm rather than >10mm, is usually 
adopted in HIV+ subjects. Mantoux skin test indurations can be associated 
with T cell immunity measured in vitro, for example, using secretion of 
IFN-γ following stimulation of diluted whole blood cultures with PPD for 
six to seven days, but this association is not perfect, with some individuals 
who show production of IFN-γ yet no detectable skin test induration, or 
large skin test indurations without detectable IFN-γ secretion; the association 
between the two tests may be weakened rather than strengthened by BCG 
vaccination (13, 14) and is less strong in infants (15). Other types of skin 
test can be performed using PPD, including the multipuncture Heaf test. It 
is worth noting that skin testing may boost an individual’s in vitro T cell 
response to mycobacterial antigens (16), and a blood draw for in vitro T cell 
functional assays should be performed at the time of administration of the 
skin test, rather than when it is read. 
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Antigen Recognition by 
Mycobacteria-Specific T Cells
Th e majority of studies investigating T cell immunity to mycobacteria have 
used PPD, produced from culture fi ltrates of MTB. PPD is used in the TST, 
in a preparation containing preservative, but preparations lacking preservative 
can be obtained for in vitro use. Equivalent PPDs can be produced from other 
mycobacterial species. As the constituent proteins in PPD are extensively 
degraded during its preparation, PPD does not require much antigen processing 
and activates predominantly CD4+ T cells. 
Whole live mycobacteria can also be used to probe the T cell response. Live 
MTB will most closely mimic the situation occurring in vivo, and induces 
stronger activation of the CD8+, γδ+, and NKT subsets than soluble antigens 
(17). Live and killed mycobacteria may induce quantitatively and qualitatively 
diff erent responses, although suspensions of live mycobacteria will also contain 
many dead bacteria. Live mycobacteria may also induce diff erent immune 
responses in peripheral blood mononuclear cells and whole blood cultures, as 
in whole blood cultures many bacteria will be phagocytosed by neutrophils, 
which then leads to apoptosis and cross-priming via macrophages. 
MTB has a genome of 4.4 Mb which contains over 4,000 genes (18), providing 
a wealth of potential antigenic targets to be recognized by T cells. An earlier 
focus on heat shock proteins has now shift ed to interest in proteins expressed 
during latency, including those induced as part of the dosR regulon (19–21). 
Th ere is continued interest in proteins secreted by MTB. Th e proteins that 
are encoded within the RD1 region in the MTB genome have been used in 
many recent studies of T cell function, particularly as the loss of the RD1 
region during the attenuation of M. bovis to form M. bovis BCG has resulted 
in ESAT-6 not being expressed by BCG (22), and thus T cell responses induced 
by BCG vaccination and MTB infection can be distinguished. ESAT-6 genes are 
found in M. marinum, M. kansasii, M. fl avescens, and M. sulzgai in addition to 
MTB; M. bovis and M. leprae also contain an ESAT-6 homologue (23). Patients 
infected with M. kansasii or M. marinum can respond to ESAT-6 from MTB 
(24), but it is not known to what extent environmental exposure to these other 
mycobacterial species can interfere with the specifi city of the two currently 
available commercial assays for TB, QuantiFERON-TB and T-SPOT-TB, which 
utilize peptides from ESAT-6 and CFP-10 (25). ESAT-6 can also have additional 
eff ects on T cell immunity, including inhibition of IFN-γ production by MTB-
specifi c human T cells (26).
Activated CD8+ T cells recognizing shorter peptides of approximately 9 
amino acids are also induced by infection with MTB (27–29). Debate continues 
about the mechanism through which mycobacterial antigens access the MHC 
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Class I pathway. Th is may be a result of the exocytosis of phagosomes (30), the 
uptake of apoptotic blebs (31, 32), or the recycling of major histocompatibility 
complex (MHC) molecules with peptide replacement. Whether MTB escapes 
into the cytoplasm is still controversial (33) but MTB does express a haemolysin 
(34) and other ESR-1 proteins such as ESAT-6 induce pore formation within 
the membrane of the phagocytic vacuole in M. marinum (35); thus antigens 
could also egress into the cytoplasm of the antigen presenting cell (APC) 
through pores in the phagosome membrane and in this way access the MHC 
Class I pathway. 
It is not just protein antigens or their constituent peptides that are recognized 
by T cells; there has been increased interest in the recognition of lipid antigens 
by CD4+ T cells (36) and ‘unconventional’ CD1-restricted T cells (37). 
Mycobacterial lipopeptides (36) can also be recognized by antigen-specifi c 
CD4+ T cells, while the γδ T cell subset can recognize phosphoantigens, 
possibly presented by novel antigen-presenting molecules (38). Th e lack of 
classical MHC restriction in the recognition of these non-protein antigens 
may give them added value as vaccine candidates. 
Cytokine Secretion by T Cells: How Good is 
IFN- as a Correlate of Protection? 
In early studies of human T cell responses to mycobacteria, the lymphocyte 
transformation test was used, assessing the incorporation of tritiated thymidine 
into proliferating cells. However more recently, measurement of cytokines has 
become the norm, and among the many products made and secreted by T 
cells, IFN-γ has received the most attention. 
Th ere are good reasons why so many studies have measured the production of 
IFN-γ. It is the signature cytokine of the Th 1 or Type 1 T cell, and plays a key role 
in macrophage activation. Mice, in which the gene for IFN-γ has been knocked 
out, become very susceptible to infection with MTB (39–41). IFN-γ can activate 
macrophages to become more bactericidal, producing greater quantities of ROI 
and RNI (2, 42, 43), although there have also been reports that IFN-γ-activated 
human macrophages do not become more mycobactericidal (44). 
In humans, there is evidence that individuals with mutations in their IFN-γR 
genes become susceptible to infections with mycobacteria (45–47). Mutations 
in other genes on the pathways that would lead to or enhance IFN-γ secretion 
such as IL-12Rβ1 or IL-12p40 (46), or in the signalling pathways downstream 
of IFN-γ also induce similar susceptibility (47). 
IFN-γ can be measured easily in immunological assays, being secreted in 
large quantities by T cells. If peripheral blood mononuclear cells are stimulated 
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with mycobacterial antigens, IFN-γ is produced and accumulates in culture 
supernatants over the fi rst seven days of culture, and its stability in culture 
supernatants has made it an easy cytokine to detect. IFN-γ released into culture 
supernatants can be measured by enzyme-linked immunosorbent assay (ELISA), 
or in bead array assays using fl ow cytometry; individual T cells secreting IFN-γ 
can be counted by enzyme-linked immunosorbent spot (ELISPOT) assay or 
by using intracellular fl ow cytometry (48). 
In vitro, shorter incubations of cultured cells for 6–24 hours are increasingly 
used, on the basis that to detect T cell activation or cytokine secretion over 
such a short time period requires the presence of a previously activated eff ector 
T cell. Longer incubation periods may provide a more sensitive read-out of 
memory responses, including those induced by past latent infection (49, 50), as 
the longer period of antigenic stimulation allows the activation and expansion 
of resting central memory T cells into eff ector T cells (51). To detect IFN-γ 
production following a short period of antigenic stimulation requires a sensitive 
detection assay, such as ELISPOT or intracellular cytokine staining.
IFN-γ is currently the main read-out of immunogenicity in TB vaccine 
trials (52, 53); but although IFN-γ is a component of protective immunity, 
there is an increasing body of evidence that it does not provide a read-out of 
protective immunity. Th is evidence includes a number of animal studies in mice, 
guinea pigs, and cattle which show that although IFN-γ may be required for 
protective immunity, the quantities of IFN-γ produced do not parallel control 
of bacterial growth (54–57). Not only does more IFN-γ production not mean 
more immunity, in some animal models greater IFN-γ production is associated 
with more pathology (58). Th ese observations, coupled with the availability 
of techniques that allow the simultaneous assessment of larger numbers of 
immune parameters, have led to intense interest in the measurement of immune 
signatures or profi les that might indicate protective immunity (59–61). 
Th e use of multiparameter fl ow cytometry is one such approach. Th e 
production of a number of cytokines or chemokines within a single cell can 
be combined with the assessment of surface phenotypic markers (62, 63). Such 
an approach can confi rm, for example, the relative contribution of CD4+ and 
CD8+ subsets to the production of key cytokines as well as the activation 
of other T cell subsets such as γδ, CD1 restricted, and NKT cells. Th e main 
cytokines usually assessed in addition to IFN-γ are TNF-α and IL-2. Th e 
current view is that cells capable of making IFN-γ, TNF-α, and IL-2 (termed 
multifunctional or polyfunctional) are a better indicator of protective immunity 
than the measurement of IFN-γ alone (64); some studies have shown that such 
polyfunctional T cells produce greater quantities of IFN-γ (as assessed by mean 
fl uorescence intensity) than T cells making IFN-γ alone (65, 66). One theory 
of memory T cell maturation proposes that cells secreting IFN-γ alone may 
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represent terminally diff erentiated cells that have lost the ability to proliferate 
(64). Other studies have shown production of GM-CSF by memory T cells 
that also produce IFN-γ and TNF (67). 
Multiparameter fl ow cytometry can be taken one stage further by using 
MHC-peptide tetramers or pentamers. Th is allows the frequency of T cells 
recognizing individual peptide epitopes to be assessed (68) and such staining 
can be combined with both surface phenotyping and intracellular cytokine 
staining. Proliferation of tetramer-positive T cells can also be assessed using 
incorporation of the dye CFSE (69). 
Th ese multiparameter fl ow cytometry techniques allow both the quantitation 
and phenotyping of antigen-specifi c T cells. However, they are likely to be 
exploratory research tools, or assays that could be performed on selected 
subjects for whom frozen peripheral blood mononuclear cells have been banked 
during a vaccine trial, for example, once these subjects have developed TB or 
have remained healthy (and thus are presumed to be protected). Th e cost and 
complexity of these assays make it unlikely that they could be performed on 
very large numbers of subjects during vaccine trials.
Additional Cytokines of Interest
Although IFN-γ, TNF-α, and IL-2 have been the cytokines most studied to 
date, other cytokines and T cell subsets have generated recent interest. Th ese 
include IL-17, produced by the Th -17 T cell subset (70). In one human study, 
the mycobacteria-specifi c T cells making IL-17 also made IFN-γ and had the 
phenotype of Th 1 central memory or eff ector memory T cells (71), whereas 
in another study IL-17 producing T cells were distinct from Th 1 T cells (72). 
In MTB-infected mice, it is γδ+ T cells rather than CD4+ T cells that are the 
major IL-17 producers (73). 
It may also be useful to assess the balance between pro-infl ammatory and 
anti-infl ammatory cytokines. IL-4 production is induced during clinical TB 
(74, 75) and may also indicate developing infection (76). Reductions in IL-4 
production can be detected shortly aft er the initiation of TB treatment (77, 78). 
Reduced IFN-γ production is also associated with the increased production of 
IL-10 which may be monocyte-derived (79). TGF-β production by regulatory 
T cells is also detected in TB infection (80, 81). Th us, the ratios between IFN-γ 
and other anti-infl ammatory cytokines may be more informative than the 
measurement of a single cytokine in isolation. 
Another way in which immune profi les can be assessed is using multiplex 
bead arrays. In these techniques a small volume of supernatant from antigen-
stimulated cultures is assayed for a number of cytokines and chemokines 
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simultaneously. Kits allowing the measurement of up to 42 analytes are currently 
available. Although the cellular origin of the analytes cannot be identifi ed 
(and such commercial kits are expensive which would again restrict their 
use to selected subjects within a vaccine trial) the ability to measure Th 1 and 
Th 2 associated cytokines, pro-infl ammatory and anti-infl ammatory cytokines, 
chemokines, and other products may allow the components of a protective 
biosignature to be identifi ed. Th ese assays are also very sensitive, allowing 
detection of cytokines such as IL-2 or IL-4 whose detection by ELISA may 
be problematic due to their rapid binding to their receptors and thus removal 
from cell cultures. A recent study from Th e Gambia using a 7-plex bead array 
showed that PPD-stimulated cultures from TB cases contained less IL-10, IL-
13, and IL-17 than TB contacts (82) while a study from South Africa using 
a 29-plex kit showed marked changes in cytokine and chemokine profi les in 
TB patients with treatment (78); results from further studies using such bead 
arrays can be expected. 
Cytotoxic Effector Function
Although CD4+ T cells usually play a central role in immunity to intracellular 
pathogens, CD8+ T cells are also important in immunity to MTB (27, 29, 83, 84). 
Murine studies have suggested that CD8+ T cells may be more important at later 
latent rather than early acute stages of MTB infection (85) but a recent study in 
non-human primates has demonstrated that removal of CD8+ T cells reduced 
BCG-induced immunity to MTB 42 days post-infection (86). MTB- specifi c CD8+ 
T cells can secrete cytokines such as IFN-γ and TNF-α, similar to CD4+ T cells 
(75). Th ey can also act as cytotoxic eff ector cells, secreting cytolytic granules into 
the contact zone between the CD8+ T cell and the infected macrophage, thus 
causing cell death. Th e action of CD8+ cytotoxic T cells on infected macrophages 
can lead to the killing of intracellular bacteria and a reduction in CFU (87). 
Th e mediators produced by such CD8+ T cells include perforin, granzymes, 
hydrolases, granulysin, and extracellular ATP. Granulysin has a direct cytotoxic 
eff ect on mycobacteria as well as on other bacteria, parasites, and fungi (88), 
and is also expressed by human NKT cells that show antimycobacterial activity 
(89). Th e eff ects of granulysin cannot be studied in mice as they do not express 
this gene. Perforin does not act directly on the mycobacteria, but the pores it 
induces are required for mycobacterial killing by both CD8+ and γδ+ T cells 
(90, 91). Another eff ect of cytotoxic T cells on infected macrophages may be to 
release the viable intracellular mycobacteria (92); this may lead to their uptake 
by more eff ective microbicidal macrophages capable of killing the mycobacteria 
using nitric oxide and other mediators.
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To measure the change in CFU following the incubation of infected monocytes/
macrophages with appropriately activated T cells may therefore provide a 
highly relevant read-out of protective immunity. A number of assays have 
been described, in which stimulated T cells are added to mycobacteria-infected 
monocyte-derived macrophages, and the CFU measured (93, 94). Th ese assays 
would, however, require simplifi cation for use on a large scale. As with some 
of the other techniques discussed in this chapter, one way forward is to freeze 
peripheral blood mononuclear cells from all vaccinees within a trial and then 
test cells from selected subjects who subsequently do or do not develop disease. 
A simpler assay uses BCG or MTB expressing the lux gene, which is added 
to diluted whole blood cultures, and bacterial growth inhibition tested using 
a luminometer, as live and metabolizing BCG-lux bacteria will produce ATP 
enabling light to be detected (95). Further work is however needed to assess 
which of these methods is most useful for the measurement of antimycobacterial 
immunity induced by vaccination. 
Identification of Novel Genes: 
Analysis of Gene Expression in T Cells 
A number of studies have used, or are currently using, gene expression as a way 
of assessing genes whose expression is induced by stimulation with MTB, during 
MTB infection, or by vaccination (96–98). Gene arrays can be used to identify 
novel genes, signalling pathways and metabolic processes that are induced by 
vaccination or during infection, using transcriptomics and new bioinformatics 
tools. As for the bead array approach, if blood or antigen-stimulated cells are 
used for RNA extraction, the cells expressing the diff erentially expressed genes 
cannot be identifi ed without further work, unless selected T cell populations 
are used for the transcriptomics (96). In addition, these analyses are better 
performed on blood samples that do not have marked increases or decreases 
of cell numbers or proportions, such as may occur in clinical disease when 
deconfounding may be required (99). 
Expression of a more limited set of genes can be evaluated by multiplex 
ligation-dependent probe amplifi cation (MLPA) assays in which expression of 
up to about 60 genes can be quantitated simultaneously (100). As with gene 
array techniques, principal component analysis may be required to identify the 
most important components that can distinguish changes in vaccinees induced 
by vaccination, or gene activation patterns that can distinguish protected from 
non-protected individuals. It will also be important to confi rm that any changes 
in gene expression are associated with changes in protein production. 
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From Small-Scale Studies to Field Trials
Once the components of a protective biosignature have been identifi ed in small-
scale in-depth studies, it will be necessary to modify the detection systems to 
allow their evaluation on a much larger scale in fi eld trials, in settings where 
laboratory facilities may be limited. For such purposes, assays that utilize 
whole blood rather than separated peripheral blood mononuclear cells may be 
preferable. Cytokine secretion and quantitation using ELISA or multiplex bead 
array assays can be performed on undiluted whole blood samples stimulated 
overnight, or diluted whole blood assays stimulated for longer periods of up 
to six to seven days to allow the activation and expansion of resting memory 
T cells. A diluted whole blood assay has been used to show the changes in 
IFN-γ production following BCG vaccination using small blood samples from 
UK and Malawian infants (101) and from adolescents and young adults in the 
same settings (14). Flow cytometry and gene expression profi les can also be 
generated from whole blood samples. 
One test parameter that should be monitored carefully in any such fi eld 
studies is the time taken to get blood samples into culture. A number of recent 
studies have shown that the number of cytokine secreting cells detected in 
ELISPOT assays, the number of cells with intracellular cytokine production, 
and the gene expression profi les within whole blood or peripheral blood 
mononuclear cells are profoundly aff ected by the time taken to get blood into 
culture (102–104) (Smith, Dockrell—unpublished results). Th us, to ensure 
interpretable results with any of these techniques, blood needs to be drawn 
into tubes containing heparin and stimuli and kept at 37 oC (102) or to be 
placed directly into PAXgeneTM tubes or another suitable RNA stabilization 
reagent. If this is not possible, the blood should be separated if required and 
cells stimulated within the minimum time period that can be realistically 
achieved, and details recorded of the time blood was taken and the time it 
was put into culture. For future deconfounding it may also be useful to have 
full blood counts performed. 
The Future: Towards Biosignatures
It is clear that measurement of one component of immunity will not be suffi  cient 
to identify protective immune responses, even if there is good evidence that 
this component is part of a protective immune response (59–61, 105). Th e 
additional components that are required may be identifi ed by a range of newer 
techniques including bead array assays or gene expression techniques. Results 
from studies evaluating changes in immune profi les with TB treatment may also 
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inform the choice of components (61, 77, 78, 106). Comparisons of immunity 
in vaccinees pre- and post-vaccination can identify changes in immune status 
induced by vaccination, and the immunogenicity of both the existing BCG 
vaccine and new candidate TB vaccines can be compared in this way. However, 
identifi cation of a biosignature of protective immunity will be more complex, 
requiring large trials in which blood samples are drawn following vaccination, 
but prior to the development of disease, as in the large infant BCG studies 
ongoing in South Africa (107). Once the key components of immunity have 
been clarifi ed, simpler assays to evaluate these genes or their products could 
be developed, enabling them to be assessed in a larger number of subjects 
within vaccine trials. In the meantime, these new approaches will contribute to 
a better understanding of the features of a protective cellular immune response 
that enable eff ective control of mycobacterial growth. 
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